核酸疗法市场规模、份额和成长分析（按产品、适应症、最终用户和地区划分）—2026-2033年产业预测

全球核酸疗法市场预计到 2024 年将达到 67 亿美元，到 2025 年将达到 76.1 亿美元，到 2033 年将达到 211.2 亿美元，预测期（2026-2033 年）的复合年增长率为 13.6%。

受新型治疗方法进展和核准数量不断增加的推动，全球核酸疗法市场正经历强劲成长。核酸（包括DNA和RNA）在细胞内讯号传导中发挥至关重要的作用，并且是治疗多种慢性疾病（包括癌症、糖尿病、癫痫、结核病和爱滋病）的关键手段。由于疗效的提升和创新药物研发策略的出现，製药和生物製药产业正受到广泛关注。随着医疗机构积极采用这些强效治疗方法，对核酸治疗方法的需求持续成长，使该市场成为现代医学和慢性病管理发展的关键参与者。这种快速增长展现了核酸疗法广阔的前景。

全球核酸疗法市场驱动因素

全球核酸疗法市场受到分子技术进步和体学研究持续探索的显着影响，促使许多公司加强投资。该市场竞争异常激烈，透过收购、合作和联合研究等多元化商务策略获取市场份额是重要的收入来源。例如，製药公司之间的策略联盟致力于发现、开发和商业化创新RNA治疗方法，以满足疫苗、感染疾病和肿瘤治疗领域的需求。此类合作对于促进创新和推动这一充满活力的领域的成长至关重要。

限制全球核酸疗法市场的因素

全球核酸疗法市场面临的关键挑战之一是如何将这些疗法有效地递送至目标细胞。成功与否取决于能否将疗法精准递送至目标组织和细胞，并最大限度地减少潜在的脱靶效应。递送过程的复杂性对致力于优化核酸疗法疗效和安全性的研究人员和开发人员构成了重大障碍。因此，开发创新的递送机制和策略仍然是业界亟待解决的问题，影响这些治疗方法的整体发展和广泛应用。

全球核酸治疗药物市场趋势

全球核酸疗法市场呈现强劲的上升趋势，这主要得益于医疗服务和研究倡议投资的持续成长。资本流入的激增主要是由于遗传性疾病和慢性病的日益普遍，促使治疗领域亟需创新。核酸技术的进步，例如基于RNA的治疗方法和基因编辑，正日益受到关注，因为它们与针对特定遗传疾病的个人化医疗方法相契合。随着医疗机构的发展和能力的提升，对核酸疗法的需求预计将会增加，从而拓展治疗选择，并改善全球患者的治疗效果。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究分析

全球核酸疗法市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 反义寡核苷酸（ASO）
• RNA干扰（RNAi）
• RNA适体

全球核酸疗法市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 自体免疫疾病
• 感染疾病
• 遗传性疾病
• 癌症
• 其他的

全球核酸疗法市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 其他的

全球核酸疗法市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Wave Life Science Ltd.（Singapore）
• Imugene（Australia）
• Aileron Therapeutics Inc.（US）
• BioNTech SE（Germany）
• Protagonist Therapeutics Inc.（US）
• Replicate Bioscience Inc.（US）
• Eli Lilly and Company（US）
• Copernicus Therapeutics Inc.（US）
• Invio Pharmaceuticals Inc.（US）
• Benitec Biopharma（Australia）
• Alnylam Pharmaceuticals（US）
• Zydus Cadila（India）
• Excision BioTherapeutics（US）
• Pfizer Inc.（US）
• Rhythm Pharmaceuticals Inc.（US）
• Axcella Health Inc.（US）

结论与建议

Global Nucleic Acid Therapeutics Market size was valued at USD 6.7 Billion in 2024 and is poised to grow from USD 7.61 Billion in 2025 to USD 21.12 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

The global nucleic acid therapeutics market is experiencing robust growth, driven by advancements in novel therapies and increased approvals. Nucleic acids, including DNA and RNA, play a crucial role in cellular information transfer and are pivotal in treating various chronic diseases such as cancer, diabetes, epilepsy, tuberculosis, and AIDS. The sector is gaining traction due to enhanced therapeutic efficacy and innovative drug development strategies within the pharmaceutical and biopharmaceutical industries. As healthcare organizations increasingly embrace these potent therapies, the demand for nucleic acid-based treatments continues to rise, positioning this market as a key player in the evolution of modern medicine and chronic disease management. This surge reflects a promising future for nucleic acid therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segments Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly influenced by advancements in molecular technologies and the continuous exploration of omics, prompting substantial investment from various companies. This market is characterized by intense competition, where gaining market share is achieved through diverse business strategies, including acquisitions, partnerships, and collaborations that serve as critical revenue channels. For instance, strategic alliances between pharmaceutical firms focus on discovering, developing, and commercializing innovative RNA-based therapies aimed at addressing needs in vaccines, infectious diseases, and oncology. Such collaborative efforts are essential for fostering innovation and driving growth within this dynamic sector.

Restraints in the Global Nucleic Acid Therapeutics Market

One significant challenge facing the Global Nucleic Acid Therapeutics market is the effective delivery of these therapies to designated target cells. Achieving successful delivery is crucial, as it requires the therapeutic agents to accurately reach the intended tissue or cells while minimizing potential off-target effects. This complexity in the delivery process poses a major obstacle for researchers and developers aiming to optimize the efficacy and safety of nucleic acid-based treatments. The need for innovative delivery mechanisms and strategies continues to be a pressing concern within the industry, impacting the overall advancement and adoption of these therapeutic modalities.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is witnessing a robust upward trend, driven by heightened investments in healthcare services and research initiatives. This surge in funding is largely attributable to the rising prevalence of genetic disorders and chronic diseases, prompting urgent innovations within therapeutic landscapes. Advances in nucleic acid technologies, such as RNA-based therapies and gene editing, are gaining traction as they align with personalized medicine approaches aimed at targeting specific genetic conditions. As healthcare facilities evolve and expand their capabilities, the demand for nucleic acid therapeutics is anticipated to grow, leading to enhanced treatment options and improved patient outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2026-2033)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations